Transgender hormone therapy (male-to-female) males is associated with higher serum estrogen. Both estrogen and testosterone help to stimulate bone formation, especially during puberty. Estrogen is the predominant sex hormone that slows bone loss, even in men. In spite of the induction of breast development, transgender women who undergo HRT do not have an increased risk of breast cancer. Only a handful of cases of breast cancer have ever been described in transgender women who have undergone male-to-female HRT. This is in accordance with research in cisgender men in which gynecomastia has been found not to be associated with an increased risk of breast cancer,
Male reproductive system during puberty causes the male secondary sexual characteristics to be manifested. the manifestation of secondary sexual characteristics include the growth of: Secondary development includes the increased activity of the eccrine sweat glands and sebaceous glands along with the darkening of the skin in the scrotal region. Chromosomal abnormalities can occur during fertilization impacting the development of the male reproductive system. The genotype of the male consists of a Y chromosome paired with an X chromosome. Female gender is determined by the absence of a Y chromosome. Some individuals are male who have the XX male syndrome and androgen insensitivity syndrome.